Get the Daily Brief
Latest Biotech News
Next‑gen cancer vaccines pull funding — clinics follow
A cluster of European cancer‑vaccine companies announced new financing and clinical progress: Accession, Infinitopes and Ervimmune secured fresh capital, with off‑the‑shelf and improved targeting...
Congress paves path for MCED coverage: appropriations include provision
The fiscal‑year appropriations bill under negotiation includes a provision to streamline Medicare coverage for FDA‑approved multi‑cancer early detection (MCED) tests, making them eligible for...
FDA drafts MRD guidance: New route for myeloma approvals
The FDA released draft guidance outlining how measurable residual disease (MRD) negativity could support accelerated approval for multiple myeloma therapies. The agency’s document, described in a...
Guardant lands FDA nod: Liquid biopsy cleared as CDx for Pfizer combo
Guardant Health won FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic to identify BRAF V600E-mutant metastatic colorectal cancer patients eligible for Pfizer's...
Corcept posts phase 3 survival win – momentum after setback
Corcept Therapeutics reported that adding relacorilant to chemotherapy reduced risk of death by 35% in a Phase 3 ovarian cancer study, a result the company said will shape its regulatory path...
GSK buys Rapt for $2.2B: Big bet on food allergy
GSK agreed to acquire Rapt Therapeutics for $2.2 billion to add ozureprubart, a long-acting anti-IgE monoclonal antibody being developed for food allergy, to its immunology portfolio. The deal...
Bristol Myers bets up to $850M on Janux T‑cell engager
Bristol Myers Squibb struck a collaboration with Janux Therapeutics focused on a tumor-activated T‑cell engager for solid tumors, paying $50 million upfront and committing up to $850 million in...
Corxel pulls $287M to fund oral GLP‑1 obesity studies
Corxel Pharmaceuticals raised up to $287 million in a Series D financing to advance its oral GLP‑1 receptor agonist through phase 2/3 obesity studies. The China‑founded company has shifted...
Ex‑BioMarin execs launch Mendra with $82M to buy rare assets
Former BioMarin executives launched Mendra, a Bay Area biotech that raised $82 million to acquire rare‑disease assets and apply AI to accelerate development. The new company will seek undervalued...
Two IND clears hit solid‑tumor pipeline — Neok and Avacta
The FDA cleared investigational new drug (IND) applications enabling first‑in‑human studies for two solid‑tumor programs. Neok Bio’s bispecific ADC NEOK‑001 received IND clearance and plans a...
Congress carves Medicare path for MCED tests in spending bill
The federal appropriations bill under discussion in Congress includes a provision creating a streamlined pathway for Medicare coverage of FDA‑approved multi‑cancer early detection (MCED) tests. If...
GSK buys Rapt for $2.2B — adds long‑acting IgE drug
GSK agreed to acquire Rapt Therapeutics for $2.2 billion to secure ozureprubart, a long‑acting anti‑IgE monoclonal antibody in Phase IIb. The deal, announced Jan. 20, consolidates GSK’s position...
FDA readies MRD pathway: draft guidance released
The U.S. Food and Drug Administration released draft guidance outlining how measurable residual disease (MRD) negativity and complete response measures could support accelerated approval in...
BMS pens $850M pact with Janux — $50M up front
Bristol Myers Squibb agreed to an up-to-$850 million collaboration with T‑cell engager company Janux Therapeutics focused on a tumor‑activated therapeutic, with $50 million payable immediately....
Erasca upsizes equity raise — $225M priced, $150M filed
Erasca priced an upsized public offering of 22.5 million shares at $10.00 per share to raise approximately $225 million, with an underwriter option for another 3.375 million shares. The financing...
Think Bioscience nets $55M to target ‘undruggable’ proteins
Think Bioscience raised $55 million in a Series A led by Regeneron Ventures and other prominent investors to advance small‑molecule programs against targets considered historically ‘undruggable.’...
BioMarin veterans launch new rare‑disease biotech with $82M
A startup founded by former BioMarin executives closed an $82 million financing to acquire and develop rare‑disease programs that need new homes or fresh development strategies. The Bay Area firm...
CMS backs Illumina test — and Guardant partners with Merck
CMS granted reimbursement for Illumina’s TruSight Oncology Comprehensive assay at $2,989.55 per test, effective Jan. 1, 2026, removing a major access barrier for comprehensive genomic profiling in...
Valneva withdraws chikungunya vaccine from US amid safety probe
Valneva voluntarily withdrew its U.S. marketing application and suspended its halted post‑marketing study for the chikungunya vaccine Ixchiq after the FDA placed a clinical hold tied to a newly...
Next‑gen biomanufacturing: self‑sufficient CHO cells and 3D‑printed bioreactors
Danish researchers engineered CHO cell lines that produce two essential amino acids (threonine and histidine) and demonstrate reduced lactate and ammonia waste, promising simpler feeding...